Assistant Professor of Research
Department of Pharmaceutical Sciences
My research interests are focused on the role of the antimicrobial protein CAP37 in vision-threatening conditions and diseases. Specifically, our goal is to develop CAP37-derived therapeutic peptides that promote corneal wound healing, prevent and treat difficult bacterial infections of the cornea, and prevent inflammation-driven diseases of the posterior segment of the eye such as age-related macular degeneration or diabetic retinopathy.
Education & Experience
- Postdoctoral Fellow, University of Texas, Dallas. Molecular Genetics. 2004
- Ph.D., Endocrinology. University of Paris XI, France. 1998.
- M.S., Cell Biology. University of Paris VII. France. 1993.
- B.S., Cell Biology. University of Paris VII. France. 1992.
- Assistant Professor of Research, Dept. of Pharmaceutical Sciences, OU College of Pharmacy. OKC, OK. 2011-present.
- Assistant Professor of Research, Dept. of Ophthalmology, OU Health Sciences Center. OKC, OK. 2004-2011.
- Postdoctoral Researcher, Dept. of Molecular Genetics. Univ. of Texas Southwestern Medical Center. Dallas, TX. 1998-2004.
- Graduate Student, Laboratoire d'Endrocrinologie Metabolisme et Developpement, CNRS UPR 1524, Meudon, France. 1994-1998.
- Research Assistant, Laboratoire de Pharmacologie et des Transports Ioniques, Univ. of Paris VII. France. 1991-1992.
Honors & Service
Awards: Travel awards to present results in international meetings, from the Association for Research in Vision and Ophthalmology Foundation (2006), the National Eye Institute (2004), the International Society for Eye Research (2004), and the Keystone Symposia (1998).
US Provisional patent appliation, 16 Apr 2014; HA Pereira, A Kasus-Jacobi, GL Briffith; "Wound healing and antibacterial compounds and methods of use."
US Provisional patent application, 03 Dec 2014; HA Pereira, A Kasus-Jacobi, GL Griffith; "CAP37 peptids as therapeutics in wound healing."
US Patent application, 03 Dec 2013; HA Pereira, A Kasus-Jacobi, GL Griffith; "Peptide compounds and methods of production and use thereof.:
US Patent US6867003 B1, 15 Mar 2005; A-F Burnol, D Perdereau, A Kasus-Jacobi, V Bereziat, J Girard; "Grb14, Grb14 fusion proteins, and screening methods."
Selected Publications & Presentations
Kasus-Jacobi A, Noor-Mohammadi S, Griffith GL, Hinsley H, Mathias L, Pereira HA. A multifunctional peptide based on the neutrophil immune defense molecule, CAP37, has antibacterial and wound-healing properties. J Leukoc Biol 2015; 97(2): 341-350.
Griffith GL, Kasus-Jacobi A, Lerner MR, Pereira HA. Corneal wound healing, a newly identified function of CAP37, is mediated by protein kinase C delta. Invest Ophthalmol Vis Sci 2014; 55: 4886-4895.
Griffith GL, Russell RA, Kasus-Jacobi A, Thavathiru E, Gonzalez ML, Logan S, Pereira HA. CAP37 activation of PKC promotes human corneal epithelial chell chemotaxis. Invest Ophthalmol Vis Sci 2013; 10.1167/iovs. 13-12054.
Marchette LD, Wang H, Li F, Babizhayev MA, Kasus-Jacobi A. Carcinine has 4-hydroxynonenal scavenging property and neuroprotective effect in mouse retina. Invest Ophthalmol Vis Sci June 2012; 53(7): 3572-2583.
Marchette LD, Thompson DA, Kravtsova M, Ngansop TN, Mandal NA, Kasus-Jacobi A. Retinol dehydrogenase 12 detoxifies 4-hydroxynonenal in photoreceptor cells. Free Radic Biol Med. 2010 Jan 1; 48(1): 16-25.
Current Grants Awarded
Identification of membrane receptor(s) for CAP37 and CAP37-derived chemotactic peptides.
The objective of this proposal is to generate preliminary results using the TriCEPS method for ligand-based receptor capture, using the CAP37 chemotactic ligands and the human corneal epithelial cells, to validate the utilization of this technical approach. OU College of Pharmacy Seed Grant, Anne Kasus-Jacobi (PI), 01/01/2015-12/31/2015.
Role of CAP37 in Neuroinflammation: Friend or Foe? The major goal of this project is to determine the role of CAP37 in neuroinflammation. Oklahoma Center for the Advancement of Scient and Technology (OCAST), HR-12-068, H. Anne Pereira (PI), Anne Kasus-Jacobi (Collaborator), 07/01/12-06/30/15.
Therapeutic use of carcinine n progressive retinopathy.
The major goal of this project was to determine whether carcinine can be used to prevent photoreceptor damage in Leber Congenital Amaurosis and Retinitis Pigmentosa mouse models. Oklahoma Center for the Advancement of Science and Technology (OCAST), HR-10-152, Anne Kasus-Jacobi (PI), 10/01/10-09/30/13.
Detoxification role of retinol dehyrogenases RDH11 and RDH12.
The major goals of this project were (1) To characterize the catalytic activities of RDH11 and RDH12 towards 4-HNE in vitro and in mouse retina; and (2) To determine whether RDH11 and RDH12 are protective against the formation of 4-HNE-protein adducts and the apoptosis of photoreceptors ex vivo and in vivo. NIH/NEI, R21EY018907, Anne Kasus-Jacobi (PI), 10/01/08-09/30/10.